Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Mayo Clinic in Arizona · Memorial Sloan Kettering Cancer Center · +9 more institutions
Abstract
PURPOSE Adagrasib, a KRAS G12C inhibitor, has demonstrated clinical activity in patients with KRAS G12C -mutated non–small-cell lung cancer (NSCLC) and colorectal cancer (CRC). KRAS G12C mutations occur rarely in other solid tumor types. We report evaluation of the clinical activity and safety of adagrasib in patients with other solid tumors harboring a KRAS G12C mutation. METHODS In this phase II cohort of the KRYSTAL-1 study (ClinicalTrials.gov identifier: NCT03785249 ; phase Ib cohort), we evaluated adagrasib (600 mg orally twice daily) in patients with KRAS G12C -mutated advanced solid tumors (excluding NSCLC and CRC). The primary end point was objective response rate. Secondary end points included…
Citation impact
- FWCI
- 79.58
- Percentile
- 100%
- References
- 37
Authors
12Topics & keywords
- KRAS
- Medicine
- Cohort
- Internal medicine
- Colorectal cancer
- Adverse effect
- Cancer
- Clinical endpoint
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- MSMemorial Sloan-Kettering Cancer CenterAward: P30 CA 008748
- ABArray BioPharma
- RPRegeneron Pharmaceuticals
- JPJazz Pharmaceuticals
- APAstex Pharmaceuticals
- LTLAM Therapeutics
- MTMersana Therapeutics
- MTMirati Therapeutics
- BBeiGene
- IIncyte
- RMRevolution Medicines
- MMacroGenics
- CBCastle Biosciences
- SSeagen
- EEisai
- APAstellas Pharma
- IIpsen
- PPlexxikon
- GGenentech
- IIgnyta
- DSDaiichi Sankyo Europe